Literature DB >> 10697968

The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds.

J Hogge1, D Krasner, H Nguyen, L B Harkless, D G Armstrong.   

Abstract

This article discusses the advantages and disadvantages of primary wound healing as compared with primary amputation in individuals with chronic diabetic foot wounds. The authors review the potential benefits of vascular surgical procedures and advanced dressings, including two of the most promising modalities in modern wound care: growth factors and bioengineered skin. In this era of cost-conscious health-care administration, it is incumbent on the practitioner to consider not only the basic science of wound care, but also the economic aspect of treatment rendered. These various interventions, dressings, growth factor delivery systems, and new modalities could significantly reduce healing time, thereby reducing the risk of infection, hospitalization, and amputation while improving quality of life. If so, they may be truly cost-effective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697968     DOI: 10.7547/87507315-90-2-57

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  3 in total

Review 1.  Literature review on the management of diabetic foot ulcer.

Authors:  Leila Yazdanpanah; Morteza Nasiri; Sara Adarvishi
Journal:  World J Diabetes       Date:  2015-02-15

2.  Electrospun poly(lactic acid-co-glycolic acid) scaffolds for skin tissue engineering.

Authors:  Sangamesh G Kumbar; Syam P Nukavarapu; Roshan James; Lakshmi S Nair; Cato T Laurencin
Journal:  Biomaterials       Date:  2008-07-21       Impact factor: 12.479

3.  Double blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON.

Authors:  Sandra Y Silva; Ligia C Rueda; Gustavo A Márquez; Marcos López; Daniel J Smith; Carlos A Calderón; Juan C Castillo; Jaime Matute; Christian F Rueda-Clausen; Arturo Orduz; Federico A Silva; Piyaporn Kampeerapappun; Mahesh Bhide; Patricio López-Jaramillo
Journal:  Trials       Date:  2007-09-26       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.